The Food and Drug Administration (FDA) has revoked the emergency use authorisation for hydroxychloroquine to treat COVID-19 patients amid the growing evidences of its inefficiency and side effects. The FDA stated that this announcement would not affect the clinical trials of the drug. The authorisation was first issued in March after some studies suggested that the anti-malarial drug might be useful against the virus.

Leave a comment